Before starting
Consider
- Baseline
- Blood pressureparticularly before COX-II inhibitors
- Estimated glomerular filtration rate
- Full blood count
- Serum creatinine
- Liver function testsif hepatic impairment
After started or dose changed
Consider
- Within 2 weeks
- Estimated glomerular filtration rate or Serum creatinine (for creatinine clearance)
- Full blood count
- Liver function testsif hepatic impairment
- Within 4 weeks; within 2 weeks if etoricoxib
- Blood pressure
- Within 4 weeks
- Haemoglobinif high risk of gastrointestinal effects
Ongoing once stable
Consider
- Periodically
- Blood pressurein elderly, high risk patients, and patients taking COX-II inhibitors
- Estimated glomerular filtration ratein renal impairment or where other drugs affecting renal function, such as ACE inhibitors
- Full blood count
- Liver function testsin liver impairment or patients on long-term NSAIDs
Notes
When to consider NSAID monitoring
NSAID monitoring may be particularly important where patients are elderly, or where there is other clinical concern which may include but is not limited to:
- ischaemic heart disease
- cardiovascular disease
- cerebrovascular disease
- peripheral vascular disease
- heart failure
- gastrointestinal disease
- renal disease
- taking drugs which may interact
Good prescribing practice
Always use NSAIDs at the lowest effective dose and for the shortest possible duration. Consider risks and response to treatment. Enquire about, and manage, adverse effects. Use clinical judgement to decide what must be monitored and how frequently. Routinely appropriateness regularly, particularly in the elderly and high risk patients.
Bibliography
- NICE Clinical Knowledge Summaries (CKS). NSAIDs prescribing issues. Last reviewed February 2024 [cited 15/06/2026].
- Joint Formulary Committee. British National Formulary : Non-steroidal anti-inflammatory drugs (online) London: BMJ Group and Pharmaceutical Press [cited 15/06/2026]
- Almirall Limited. Summary of Product Characteristics – Preservex 100mg film-coated tablets. Last revised 07/03/2023 [cited 15/06/2026]
- Aurobindo Pharma – Milpharm Ltd. Summary of Product Characteristics – Celecoxib 200mg capsules. Last revised 13/05/2026 [cited 15/06/2026]
- A.Menarini Farmaceutica Internazionale SRL. Summary of Product Characteristics – Keral 25mg film-coated tablets. Last revised 09/2025 [cited 15/06/2026]
- Dexcel Pharma Ltd. Summary of Product Characteristics – Diclofenac sodium Dexcel XL 100mg prolonged-release tablets. Last revised 16/04/2026 [cited 15/06/2026]
- Merck Sharp & Dohme Limited. Summary of Product Characteristics – Arcoxia 120 mg Film-coated Tablets. Last revised 04/2025 [cited 15/06/2026]
- Almirall Limited. Summary of Product Characteristics – Lodine 600mg ST tablets. Last revised 05/2026 [cited 15/06/2026]
- Viatris. Summary of Product Characteristics – Flurbiprofen 100mg coated tablets. Last revised 10/2025 [cited 15/06/2026]
- Strides Pharma UK Ltd. Summary of Product Characteristics – Ibuprofen 400mg tablets. Last revised 10/10/2024 [cited 15/06/2026]
- Strides Pharma UK Ltd. Summary of Product Characteristics – Mefenamic acid 500mg film-coated tablets. Last revised 15/03/2023 [cited 15/06/2026]
- Tillomed Laboratories Ltd. Summary of Product Characteristics – Nabumetone 500mg film-coated tablets. Last revised 18/07/2023 [cited 15/06/2026]
- Atnahs Pharma UK Ltd. Summary of Product Characteristics – Naprosyn 500mg Tablets. Last revised 8/8/2024 [cited 15/06/2026]
- Strides Pharma UK Ltd. Summary of Product Characteristics – Piroxicam 10mg capsules. Last revised 14/10/2023 [cited 15/06/2026]
Update history
- Full review and update. No change to content.
- Published